基于血液的DNA甲基化谱用于卵巢癌检测
本研究对152份组织和373份血液样本进行靶向亚硫酸氢盐测序,基于组织差异甲基化区域构建机器学习模型,在178例训练队列中交叉验证,并在184例独立测试队列中评估。模型在测试集中总体预测准确率为89.5%,对I-II期卵巢癌的准确预测率为44.4%。
要点
- 基于组织差异甲基化区域构建的机器学习模型在训练集五折交叉验证中曲线下面积为0.94。
- 测试集中模型对健康女性非恶性肿瘤预测准确率为96.2%(n=53),对良性肿瘤女性为93.5%(n=46)。
- 测试集中模型对恶性肿瘤的预测准确率:I-II期为44.4%(n=9),III期为86.4%(n=59),IV期为100.0%(n=6),分期未知为81.8%(n=11)。
核心结论
- 本研究显示基于血液的DNA甲基化谱用于卵巢癌检测具有潜在的临床应用价值。
研究设计与样本
- 对来自健康女性、良性卵巢肿瘤女性或恶性上皮性卵巢肿瘤女性的组织样本(n=152)和血液样本(n=373)进行靶向亚硫酸氢盐测序。
- 基于组织来源的差异甲基化区域,采用监督机器学习算法,利用训练队列(n=178)的血液DNA甲基化谱进行交叉验证,以预测和分类每份血液样本为恶性或非恶性。
- 模型进一步在独立测试队列(n=184)中评估。
主要发现
- 比较正常/良性肿瘤与恶性肿瘤样本的DNA甲基化谱,鉴定出1272个差异甲基化区域,其中49.4%为高甲基化区域,50.6%为低甲基化区域。
- 使用训练数据集对模型进行五折交叉验证,曲线下面积为0.94。
- 在测试数据集中,模型准确预测非恶性状态:健康女性为96.2%(n=53),良性肿瘤女性为93.5%(n=46)。
- 在测试数据集中,模型准确预测恶性状态:I-II期肿瘤为44.4%(n=9),III期肿瘤为86.4%(n=59),IV期肿瘤为100.0%(n=6),分期未知肿瘤为81.8%(n=11)。
- 总体而言,模型预测准确率为89.5%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Ovarian cancer is a fatal gynecological cancer due to the lack of effective screening strategies at early stage. This study explored the utility of DNA methylation profiling of blood samples for the detection of ovarian cancer. METHODS: Targeted bisulfite sequencing was performed on tissue (n = 152) and blood samples (n = 373) obtained from healthy women, women with benign ovarian tumors, or malignant epithelial ovarian tumors. Based on the tissue-derived differentially-methylated regions, a supervised machine learning algorithm was implemented and cross-validated using the blood-derived DNA methylation profiles of the training cohort (n = 178) to predict and classify each blood sample as malignant or non-malignant. The model was further evaluated using an independent test cohort (n = 184). RESULTS: Comparison of the DNA methylation profiles of normal/benign and malignant tumor samples identified 1272 differentially-methylated regions, with 49.4% hypermethylated regions and 50.6% hypomethylated regions. Five-fold cross-validation of the model using the training dataset yielded an area under the curve of 0.94. Using the test dataset, the model accurately predicted non-malignancy in 96.2% of healthy women (n = 53) and 93.5% of women with benign tumors (n = 46). For patients with malignant tumors, the model accurately predicted malignancy in 44.4% of stage I-II (n = 9), 86.4% of stage III (n = 59), 100.0% of stage IV tumors (n = 6), and 81.8% of tumors with unknown stage (n = 11). Overall, the model yielded a predictive accuracy of 89.5%. CONCLUSIONS: Our study demonstrates the potential clinical application of blood-based DNA methylation profiling for the detection of ovarian cancer.
引用
- Li N, Zhu X, Nian W, et al. Blood-based DNA methylation profiling for the detection of ovarian cancer. Gynecol Oncol. 2022. PMID: 36096974. doi:10.1016/j.ygyno.2022.07.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。